等待開盤 11-07 09:30:00 美东时间
+0.160
+0.67%
今日重点评级关注:Citizens:维持Precigen"跑赢大市"评级,目标价从11美元升至12美元;Leerink Partners:维持Arcus Biosciences"跑赢大市"评级,目标价从46美元升至49美元
11-06 16:15
Veracyte Inc. (NASDAQ:VCYT) stock traded lower Thursday after the company reported weaker-than-expected Decipher Prostate test volume despite beating third-quarter earnings and revenue estimates. The diagnostics company also announced a $100 million share buyback program. Veracyte Beats Third-Quarte...
11-06 00:29
华盛资讯11月5日讯,Veracyte公布2026财年Q3业绩,公司Q3营收1.52亿美元,同比增长15.1%,归母净利润0.32亿美元,同比增长64.6%。
11-05 21:16
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $69 to $46.
11-05 18:34
华盛资讯11月5日讯,Veracyte公布2026财年Q3业绩,公司Q3营收1.52亿美元,同比增长15.1%,归母净利润0.32亿美元,同比增长64.6%。
11-05 08:55
https://www.sec.gov/ix?doc=/Archives/edgar/data/1384101/000138410126000053/vcyt-20261104.htm
11-05 06:21
Veracyte shares are trading lower after the company reported Q3 financial results and narrowed its FY26 sales guidance below estimates.
11-05 05:56
Veracyte (NASDAQ:VCYT) narrows FY2026 sales outlook from $590.000 million-$596.000 million to $590.000 million-$593.000 million vs $593.894 million estimate.
11-05 05:34